A potential overlap between the first OTC daily oral contraceptive proposed in the US and the “additional conditions for nonprescription use” the Food and Drug Administration is considering for OTC approvals is noted in comments to the agency on each of the topics.
The FDA hasn’t referenced the other topic in all of its notices and announcements about either Perrigo Company plc business HRA Pharma’s new drug application to make 0
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?